|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Clinician-reported event** | Baseline (N=20) | 3 months (N=20) | 6 months (N=20) | 12 months (N=10) | p |
| Abdominal pain | - | 20% | 25% | 30% | 0.05 |
| Alopecia | - | 5% | 15% | 10% | 0.40 |
| Arthralgia | 40% | 65% | 60% | 30% | 0.20 |
| Asthenia/Fatigue | 50% | 90% | 80% | 80% | 0.04 |
| Constipation | 25% | 35% | 45% | 20% | 0.48 |
| Decreased appetite | 15% | 50% | 50% | 30% | 0.06 |
| Diarrhoea | - | 5% | 20% | 50% | <0.01 |
| Dysphonia | 60% | 55% | 40% | 40% | 0.59 |
| Dysgeusia | 5% | 30% | 30% | 20% | 0.14 |
| Hand-foot syndrome | - | 30% | 55% | 40% | <0.01 |
| Headache | 30% | 15% | 20% | 10% | 0.63 |
| Myalgia | 35% | 55% | 60% | 40% | 0.42 |
| Nausea | 5% | 15% | 25% | 10% | 0.39 |
| Peripheral edema | 5% | 5% | 15% | 10% | 0.78 |
| Rash | - | 10% | - | 10% | 0.22 |
| Stomatitis | 5% | 30% | 25% | 20% | 0.18 |
| Xerostomia | 10% | 55% | 25% | 60% | <0.01 |
| Vomiting | - | 5% | 15% | 10% | 0.40 |

**Supplementary Table 1.** Clinician’s assessment of symptomatic events (all grades) at baseline and at 3, 6 and 12 months after the start of treatment. Only AEs included in the PRO-CTCAE questionnaire were reported.

Abbreviations: AEs, adverse events; PRO-CTCAE, Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events